Abstract
Familial lecithin-cholesterol acyltransferase deficiency (FLD) is a rare recessive disorder of cholesterol metabolism, caused by loss-of-function mutations in the human LCAT gene, leading to alterations in the lipid/lipoprotein profile, with extremely low HDL levels.
The classical FLD phenotype is characterized by diffuse corneal opacification, haemolytic anaemia and proteinuric chronic kidney disease (CKD); an incomplete form, only affecting the corneas, has been reported in a few families worldwide.
We describe an intermediate phenotype of LCAT deficiency, with CKD preceding the development of corneal clouding, in two Portuguese brothers apparently homozygous for a novel missense LCAT gene mutation. The atypical phenotype, the diagnosis of membranous nephropathy in the proband’s native kidney biopsy, the late-onset and delayed recognition of the corneal opacification, the co-segregation with Gilbert syndrome and the late recurrence of the primary disease in kidney allograft all contributed to obscure the diagnosis of an LCAT deficiency syndrome for many years.
A major teaching point is that on standard light microscopy examination the kidney biopsies of patients with LCAT deficiency with residual enzyme activity may not show significant vacuolization and may be misdiagnosed as membranous nephropathy. The cases of these two patients also illustrate the importance of performing detailed physical examination in young adults presenting with proteinuric CKD, as the most important clue to the diagnosis of FLD is in the eyes.
Keywords
This is a preview of subscription content, log in via an institution.
Reference
Aranda P, Valdivielso P, Pisciotta L et al (2008) Therapeutic management of a new case of LCAT deficiency with a multifactorial long-term approach based on high doses of angiotensin II receptor blockers (ARBs). Clin Nephrol 69:213–218
Calabresi L, Pisciotta L, Costantin A et al (2005) The molecular basis of lecithin-cholesterol acyltransferase deficiency syndromes: a comprehensive study of molecular and biochemical findings in 13 unrelated Italian families. Arterioscler Thromb Vasc Biol 25:1972–1978
Calabresi L, Baldassarre D, Castelnuovo S et al (2009) Functional lecithin-cholesterol acyltransferase is not required for efficient atheroprotection in humans. Circulation 120:628–635
Charlton-Menys V, Pisciotta L, Durrington PN et al (2007) Molecular characterization of two patients with severe LCAT deficiency. Nephrol Dial Transplant 22:2379–2382
De Buyzere M, Delanghe J, Labeur C et al (1992) Acquired hypolipoproteinemia. Clin Chem 38:776–781
Hirashio S, Ueno T, Naito T, Masaki T (2014) Characteristic kidney pathology, gene abnormality and treatments in LCAT deficiency. Clin Exp Nephrol 18:189–193
Kettritz R, Elitok S, Koepke ML, Kuchenbecker J, Schneider W, Luft FC (2009) The case: the eyes have it! Kidney Int 76:465–466
Kuivenhoven JA, Pritchard H, Hill J et al (1997) The molecular pathology of lecithin-cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res 38:191–205
Kunnen S, Van Eck M (2012) Lecithin-cholesterol acyltransferase: old friend or foe in atherosclerosis? J Lipid Res 53:1783–1799
Lambert G, Sakai N, Vaisman BL et al (2001) Analysis of glomerulosclerosis and atherosclerosis in lecithin-cholesterol acyltransferase deficient mice. J Biol Chem 276:15090–15098
Liew H, Simpson I, Kanellis J, Mulley WR (2016) Recurrent glomerulopathy in a renal allograft due to lecithin-cholesterol acyltransferase deficiency. Nephrology (Carlton) 21(1):73–74
Lynn EG, Siow YL, Frohlich J, Cheung GT, O K (2001) Lipoprotein-X stimulates monocyte chemoattractant protein-1 expression in mesangial cells via nuclear factor-kappa B. Kidney Int 60:520–532
Miarka P, Idzior-Waluœ B, KuŸniewski M, Waluœ-Miarka M, Klupa T, Sułowicz W (2011) Corticosteroid treatment of kidney disease in a patient with familial lecithin-cholesterol acyltransferase deficiency. Clin Exp Nephrol 15:424–429
Myhre E, Gjone E, Flatmark A, Hovig T (1977) Renal failure in familial lecithin-cholesterol acyltransferase deficiency. Nephron 18:239–248
Nishiwaki M, Ikewaki K, Bader G et al (2006) Human lecithin-cholesterol acyltransferase deficiency: in vivo kinetics of low-density lipoprotein and lipoprotein-X. Arterioscler Thromb Vasc Biol 26:1370–1375
Ossoli A, Neufeld EB, Thacker SG et al (2016) Lipoprotein X causes renal disease in LCAT deficiency. PLoS One 11(2):e0150083
Palmiero P-M, Sbeity Z, Liebmann J, Ritch R (2009) In vivo imaging of the cornea in a patient with lecithin-cholesterol acyltransferase deficiency. Cornea 29:1061–1064
Panescu V, Grignon Y, Hestin D et al (1997) Recurrence of lecithin-cholesterol acyltransferase deficiency after kidney transplantation. Nephrol Dial Transplant 12:2430–2432
Rousset X, Vaisman B, Auerbach B et al (2010) Effect of recombinant human lecithin-cholesterol acyltransferase infusion on lipoprotein metabolism in mice. J Pharmacol Exp Ther 335(1):140–148
Santamarina-Fojo S, Hoeg J, Assmann G, Brewer HBJ (2001) Lecithin-cholesterol acyltransferase deficiency and fish eye disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 2817–2833
Shamburek RD, Bakker-Arkema R, Auerbach BJ et al (2016a) Familial lecithin-cholesterol acyltransferase deficiency: first-in-human treatment with enzyme replacement. J Clin Lipidol 10(2):356–367
Shamburek RD, Bakker-Arkema R, Shamburek AM et al (2016b) Safety and tolerability of ACP-501, a recombinant human lecithin-cholesterol acyltransferase, in a phase 1 single-dose escalation study. Circ Res 118(1):73–82
Simonelli S, Tinti C, Salvini L et al (2013) Recombinant human LCAT normalizes plasma lipoprotein profile in LCAT deficiency. Biologicals 41:446–449
Skretting G, Blomhoff JP, Solheim J, Prydz H (1992) The genetic defect of the original Norwegian lecithin-cholesterol acyltransferase deficiency families. FEBS Lett 309:307–310
Strom EH, Sund S, Reier-Nilsen M, Dorje C, Leren TP (2011) Lecithin-cholesterol acyltransferase (LCAT) deficiency: renal lesions with early graft recurrence. Ultrastruct Pathol 35:139–145
Takahashi S, Hiromura K, Tsukida M et al (2013) Nephrotic syndrome caused by immune-mediated acquired LCAT deficiency. J Am Soc Nephrol 24:1305–1312
Yee MS, Pavitt DV, Richmond W et al (2009) Changes in lipoprotein profile and urinary albumin excretion in familial LCAT deficiency with lipid lowering therapy. Atherosclerosis 205:528–532
Acknowledgements
We thank the patients and their mother and older sister for having participated in this study and consented to its publication.
The LCAT gene mutational analysis of the proband was performed at GENDIA (GENetic DIAgnostic Network; http://www.gendia.net/), purchased as an outsource laboratory service.
The UGT1A1 promoter sequence analysis was performed at the “Instituto de Genética Médica Jacinto Magalhães” (Porto, Portugal), purchased as an outsource laboratory service.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Communicated by: Robert Steiner
Appendices
Take Home Message
LCAT deficiency diagnosis may be misleading, particularly in atypical phenotypes, highlighting the importance of a detailed physical examination in patients presenting with proteinuric CKD, as the most important clue to the diagnosis of FLD is in the eyes.
Details of the Contributions of Individual Authors
- Dr. Inês Castro Ferreira:
-
provided clinical data and drafted the manuscript;
- Dr. Rute Carmo:
-
performed the kidney biopsy and drafted the manuscript;
- Dr. Sérgio Estrela Silva:
-
performed the ophthalmological examinations and provided clinical data and the relevant photographs;
- Dr. Otília Corrêa:
-
performed the lipid and lipoprotein analyses;
- Dr. Susana Fernandes:
-
performed the LCAT genetic analysis and provided the electropherogram;
- Dr. Susana Sampaio:
-
performed histopathological evaluation of kidney allograft biopsies and provided the relevant illustrations/photographs;
- Dr. Pedro Rodrigues Pereira:
-
performed histopathological evaluation of kidney allograft biopsies and provided the relevant illustrations/photographs;
- Dr. Augusta Praça:
-
provided clinical data;
- Prof. Dr. João Paulo Oliveira:
-
provided clinical data and drafted the manuscript and is the guarantor for the chapter.
Corresponding Author
I. Castro-Ferreira.
E-mail: inescastroferreira@sapo.pt.
Details of Funding
None.
Compliance with Ethics Guidelines
Conflict of Interest
Inês Castro Ferreira, Rute Carmo, Sérgio Estrela Silva, Otília Corrêa, Susana Fernandes, Susana Sampaio, Pedro Rodrigues Pereira, Augusta Praça and João Paulo Oliveira declare that they have no conflict of interest.
Informed Consent
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study.
Ethical Standards
There are no identifiable patient’s personal data on this manuscript.
The publication of this manuscript was approved by the Committee on Ethics for Health of the Centro Hospitalar São João/Faculdade de Medicina da Universidade do Porto.
Rights and permissions
Copyright information
© 2017 Society for the Study of Inborn Errors of Metabolism (SSIEM)
About this chapter
Cite this chapter
Castro-Ferreira, I. et al. (2017). Novel Missense LCAT Gene Mutation Associated with an Atypical Phenotype of Familial LCAT Deficiency in Two Portuguese Brothers. In: Morava, E., Baumgartner, M., Patterson, M., Rahman, S., Zschocke, J., Peters, V. (eds) JIMD Reports, Volume 40. JIMD Reports, vol 40. Springer, Berlin, Heidelberg. https://doi.org/10.1007/8904_2017_57
Download citation
DOI: https://doi.org/10.1007/8904_2017_57
Received:
Revised:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-57879-7
Online ISBN: 978-3-662-57880-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)